Induced Intermediate Mesoderm Combined with Decellularized Kidney Scaffolds for Functional Engineering Kidney.
Adipose-derived stem cells
Decellularized scaffolds
Induced differentiation
Intermediate mesoderm cells
Kidney regeneration
Journal
Tissue engineering and regenerative medicine
ISSN: 2212-5469
Titre abrégé: Tissue Eng Regen Med
Pays: Korea (South)
ID NLM: 101699923
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
01
01
2019
revised:
17
04
2019
accepted:
29
05
2019
entrez:
19
10
2019
pubmed:
19
10
2019
medline:
19
10
2019
Statut:
epublish
Résumé
Chronic kidney disease is a severe threat to human health with no ideal treatment strategy. Mature mammalian kidneys have a fixed number of nephrons, and regeneration is difficult once they are damaged. For this reason, developing an efficient approach to achieve kidney regeneration is necessary. The technology of the combination of decellularized kidney scaffolds with stem cells has emerged as a new strategy; however, in previous studies, the differentiation of stem cells in decellularized scaffolds was insufficient for functional kidney regeneration, and many problems remain. We used 0.5% sodium dodecyl sulfate (SDS) to produce rat kidney decellularized scaffolds, and induce adipose-derived stem cells (ADSCs) into intermediate mesoderm by adding Wnt agonist CHIR99021 and FGF9 Intermediate mesoderm cells were successfully induced from ADSCs and identified by immunofluorescence and Western blotting assays (OSR1 + , PAX2 +). Immunofluorescence showed that intermediate mesoderm cells differentiated into tubular-like (E-CAD + , GATA3 +) and podocyte-like (WT1 +) cells with higher differentiation efficiency than ADSCs in the decellularized scaffolds. Comparatively, this phenomenon was not observed in induced intermediate mesoderm cells cultured In this study, we demonstrated that intermediate mesoderm cells could be induced from ADSCs and that they could differentiate well after cocultured with decellularized scaffolds.
Sections du résumé
Background
Chronic kidney disease is a severe threat to human health with no ideal treatment strategy. Mature mammalian kidneys have a fixed number of nephrons, and regeneration is difficult once they are damaged. For this reason, developing an efficient approach to achieve kidney regeneration is necessary. The technology of the combination of decellularized kidney scaffolds with stem cells has emerged as a new strategy; however, in previous studies, the differentiation of stem cells in decellularized scaffolds was insufficient for functional kidney regeneration, and many problems remain.
Methods
We used 0.5% sodium dodecyl sulfate (SDS) to produce rat kidney decellularized scaffolds, and induce adipose-derived stem cells (ADSCs) into intermediate mesoderm by adding Wnt agonist CHIR99021 and FGF9
Results
Intermediate mesoderm cells were successfully induced from ADSCs and identified by immunofluorescence and Western blotting assays (OSR1 + , PAX2 +). Immunofluorescence showed that intermediate mesoderm cells differentiated into tubular-like (E-CAD + , GATA3 +) and podocyte-like (WT1 +) cells with higher differentiation efficiency than ADSCs in the decellularized scaffolds. Comparatively, this phenomenon was not observed in induced intermediate mesoderm cells cultured
Conclusion
In this study, we demonstrated that intermediate mesoderm cells could be induced from ADSCs and that they could differentiate well after cocultured with decellularized scaffolds.
Identifiants
pubmed: 31624705
doi: 10.1007/s13770-019-00197-9
pii: 197
pmc: PMC6778583
doi:
Substances chimiques
Chir 99021
0
Fibroblast Growth Factor 9
0
Pyridines
0
Pyrimidines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
501-512Informations de copyright
© The Korean Tissue Engineering and Regenerative Medicine Society 2019.
Déclaration de conflit d'intérêts
Conflict of interestAll authors declare that there is no conflict of interest.
Références
Lancet. 2015 May 16;385(9981):1975-82
pubmed: 25777665
J Appl Biomater Funct Mater. 2017 Nov 11;15(4):e326-e333
pubmed: 29131298
Kidney Int. 1999 Jun;55(6):2502-14
pubmed: 10354300
Dev Biol. 2002 Mar 1;243(1):128-36
pubmed: 11846482
Methods Mol Biol. 2017;1597:195-206
pubmed: 28361319
Heart Vessels. 2016 Nov;31(11):1874-1881
pubmed: 27129706
Biomaterials. 2012 Nov;33(31):7756-64
pubmed: 22841923
Nature. 1994 Dec 15;372(6507):679-83
pubmed: 7990960
Differentiation. 2012 Oct;84(3):223-31
pubmed: 22885322
PLoS One. 2017 Mar 7;12(3):e0173040
pubmed: 28267813
Development. 2007 Sep;134(17):3177-90
pubmed: 17693601
Stem Cells Int. 2015;2015:724047
pubmed: 26089921
Cells Tissues Organs. 2012;195(3):197-206
pubmed: 21494022
Nature. 2015 Oct 22;526(7574):564-8
pubmed: 26444236
Tissue Eng Part B Rev. 2017 Jun;23(3):211-224
pubmed: 28457175
Ann Anat. 2015 Nov;202:8-17
pubmed: 26335195
Mol Med Rep. 2015 Nov;12(5):6835-40
pubmed: 26352155
Acta Biomater. 2016 Sep 15;42:46-55
pubmed: 27375285
Front Physiol. 2014 Sep 26;5:354
pubmed: 25309452
Cell Transplant. 2013;22(4):701-9
pubmed: 23068312
N Engl J Med. 1999 Dec 2;341(23):1725-30
pubmed: 10580071
Am J Pathol. 2012 Jun;180(6):2417-26
pubmed: 22507837
Pediatr Nephrol. 2003 Aug;18(8):731-42
pubmed: 12811645
Sci Rep. 2017 Dec 22;7(1):18053
pubmed: 29273785
Mol Biol Cell. 2002 Dec;13(12):4279-95
pubmed: 12475952
J Biomed Mater Res A. 2018 Mar;106(3):805-814
pubmed: 29067774
Oncotarget. 2015 Nov 3;6(34):36126-38
pubmed: 26418881
J Am Soc Nephrol. 2009 Nov;20(11):2338-47
pubmed: 19729441
J Assoc Res Otolaryngol. 2013 Feb;14(1):3-15
pubmed: 23085833
Tissue Eng Part A. 2014 May;20(9-10):1486-98
pubmed: 24320825
Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2 Suppl):59-64
pubmed: 21781447
Kidney Int. 2009 Oct;76(8):825-30
pubmed: 19625995
Biomaterials. 2013 Dec;34(38):9830-41
pubmed: 24074840
Bioessays. 2006 Feb;28(2):117-27
pubmed: 16435290
Cytotherapy. 2012 Nov;14(10):1203-14
pubmed: 22909277
Mech Dev. 2005 Jun;122(6):765-80
pubmed: 15905075
Lancet. 2013 Jul 20;382(9888):260-72
pubmed: 23727169
Transl Res. 2014 Apr;163(4):268-85
pubmed: 24291155
World J Gastroenterol. 2017 Oct 14;23(38):6973-6982
pubmed: 29097870
Trends Mol Med. 2011 Aug;17(8):424-32
pubmed: 21514224
J Cell Mol Med. 2010 Apr;14(4):878-89
pubmed: 20070436
Development. 2007 Jul;134(13):2533-9
pubmed: 17537789
Cell Biochem Funct. 2008 Aug;26(6):664-75
pubmed: 18636461
Curr Opin Biotechnol. 2013 Oct;24(5):830-3
pubmed: 23726156
Stem Cell Rev Rep. 2017 Aug;13(4):513-531
pubmed: 28239758